Related Experiment Video

Updated: Feb 27, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

843

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex

Gilles Safa1

  • 1Department of Dermatology, Centre Hospitalier de Saint-Brieuc, Saint-Brieuc, France.

Oxford Medical Case Reports
|July 11, 2017
PubMed

Insights

Topical rapamycin offers a promising treatment for facial angiofibromas, a common symptom of tuberous sclerosis complex. This case study shows successful treatment with rapamycin, improving patient quality of life with minimal side effects.

Area of Science:

  • Dermatology
  • Genetics
  • Pharmacology

Background:

  • Facial angiofibromas are a frequent dermatological sign of tuberous sclerosis complex (TSC).
  • These benign tumors, while often asymptomatic, can cause significant disfigurement and negatively impact patients' quality of life.
  • Current treatment options for facial angiofibromas are limited and often challenging.

Observation:

  • A case report details the treatment of a 27-year-old woman with facial angiofibromas associated with TSC.
  • The patient presented with significant cosmetic concerns due to the angiofibromas.
  • The focus was on evaluating the efficacy and safety of a novel topical treatment.

Findings:

  • Topical rapamycin was administered to treat the patient's facial angiofibromas.
  • The treatment resulted in successful reduction of the angiofibromas.
  • No significant adverse side effects were reported during the treatment period.

Implications:

  • Topical rapamycin presents a potentially effective and safe therapeutic option for managing facial angiofibromas in tuberous sclerosis complex patients.
  • This approach may offer an improved quality of life for individuals affected by TSC-related facial disfigurement.
  • Further clinical studies are warranted to confirm these findings in a larger patient cohort.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.8K
A Patient-Derived Xenograft Model for Venous Malformation06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K